Drug intelligence / Profile preview

lactobacillus gasseri 177

Development stage: Unknown
Lead developer: Estonian Science Foundation
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus gasseri 177 is a specific probiotic bacterial strain identified and studied by researchers at the University of Tartu, with funding from the Estonian Science Foundation (Grant 6116). It was developed as part of a biodefense initiative to identify lactobacilli capable of surviving the human gastrointestinal tract and providing protection against bioterrorism agents. The strain's mechanism of action involves the stabilization of the gut microbiota, competitive inhibition of pathogenic colonization, and potential enhancement of mucosal immunity. Clinical evaluation has focused on its safety, tolerability, and persistence in the gut following oral administration in healthy volunteers.

Other names: Lactobacillus gasseri strain 177

Beyond the preview

Go deeper on lactobacillus gasseri 177.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus gasseri 177.

Explore the full profile